A-5959 Azacitidine, Free Base, >99%

Synonyms : [5-AzaC] [5-Azacytidine] [5-AZC] [5-AZCR] [5-Azacitidine] [Azacitidinum] [Ladakamycin] [Ledakamycin] [U 18496] [WR 183027]

Related Terms : [Mylosar] [Vidaza]

New
  • Size
  • US $
  • £
  • ¥
  • 100 mg
  • 37
  • 31
  • 28
  • 4,000
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 64
  • 54
  • 49
  • 7,000
  • Add to Cart Qty:
  • In stock
  • 250 mg
  • 75
  • 63
  • 58
  • 8,200
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 112
  • 95
  • 87
  • 12,200
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 167
  • 141
  • 130
  • 18,200
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 252
  • 214
  • 196
  • 27,500
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 445
  • 378
  • 347
  • 48,600
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 680
  • 578
  • 530
  • 74,200
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 244.20
  • C8H12N4O5
  • [320-67-2]

Certificate of Analysis

  • Azacitidine is a chemical analog of cytidine, a nucleoside found in DNA and RNA. It inhibits DNA methyltransferase and leads to hypomethylation in the promoter region of transcriptionally silenced genes. Azacytidine demonstrated significant cytotoxicity against both conventional therapy-sensitive and therapy-resistant multiple myeloma (MM) cell lines, as well as multidrug-resistant patient-derived MM cells, with IC50 values of approximately 0.8-3 μM. Azacytidine treatment induced DNA double-strand breaks and apoptosis of MM cells. Kiziltepe T., et al. "5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells." Mol. Cancer Ther. 6: 1718-1727 (2007).
  • Azacitidine is the active ingredient in the drug product sold under the trade names Mylosar and Vidaza®. This drug is currently approved in at least one country for use in patients with myelodysplastic syndrome. NOTE: THE AZACITIDINE, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT MYLOSAR OR VIDAZA®, AND IS NOT FOR HUMAN USE.
  • Related CAS numbers: 879492-75-8 for the methanesulfonate salt; 1401238-96-7 for the sulfate salt; 1401238-97-8 for the hydrobromide salt.
  • Other CAS numbers previously assigned to 5-Azacitidine, Free Base, namely 52934-49-3 and 292869-98-8, have been deleted by CAS and are no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
1339